Hypoxia-Inducible Factors: Mediators of Cancer Progression; Prognostic and Therapeutic Targets in Soft Tissue Sarcomas
出版年份 2013 全文链接
标题
Hypoxia-Inducible Factors: Mediators of Cancer Progression; Prognostic and Therapeutic Targets in Soft Tissue Sarcomas
作者
关键词
-
出版物
Cancers
Volume 5, Issue 4, Pages 320-333
出版商
MDPI AG
发表日期
2013-04-03
DOI
10.3390/cancers5020320
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- High Expression of HIF1a Is a Predictor of Clinical Outcome in Patients with Pancreatic Ductal Adenocarcinomas and Correlated to PDGFA, VEGF, and bFGF
- (2015) Andreas-Claudius Hoffmann et al. NEOPLASIA
- Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma
- (2012) M. M. Mita et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Gene expression identifies heterogeneity of metastatic propensity in high-grade soft tissue sarcomas
- (2012) Keith M. Skubitz et al. CANCER
- Targeting hypoxia brings breath of fresh air to cancer therapy
- (2012) Melinda Wenner Moyer NATURE MEDICINE
- Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
- (2012) Annamaria Rapisarda et al. Nature Reviews Clinical Oncology
- Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
- (2012) Gregg L. Semenza TRENDS IN PHARMACOLOGICAL SCIENCES
- Treating metastatic soft-tissue or bone sarcomas – potential role of ridaforolimus
- (2012) Vicki Keedy OncoTargets and Therapy
- Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects
- (2011) Puja Sapra et al. ANGIOGENESIS
- Association of Elevated HIF-2α Levels with Low Beclin 1 Expression and Poor Prognosis in Patients with Chondrosarcoma
- (2011) Changbao Chen et al. ANNALS OF SURGICAL ONCOLOGY
- Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads
- (2011) Annamaria Rapisarda et al. CELL CYCLE
- Roles of the human hypoxia-inducible factor (HIF)-3α variants in the hypoxia response
- (2011) Minna Heikkilä et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
- (2011) Sant P. Chawla et al. JOURNAL OF CLINICAL ONCOLOGY
- Interplay between HDAC3 and WDR5 Is Essential for Hypoxia-Induced Epithelial-Mesenchymal Transition
- (2011) Min-Zu Wu et al. MOLECULAR CELL
- A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma
- (2011) Kristen N. Ganjoo et al. ONCOLOGY
- Amplification of the Angiogenic Signal through the Activation of the TSC/mTOR/HIF Axis by the KSHV vGPCR in Kaposi's Sarcoma
- (2011) Bruno C. Jham et al. PLoS One
- Hypoxia and hypoglycaemia in Ewing's sarcoma and osteosarcoma: regulation and phenotypic effects of Hypoxia-Inducible Factor
- (2010) Helen J Knowles et al. BMC CANCER
- Analysis of HIF-1a and its regulator, PHD2, in retroperitoneal sarcomas: clinico-pathologic implications
- (2010) Jui-Han Huang et al. CANCER BIOLOGY & THERAPY
- Hypoxia Modulates EWS-FLI1 Transcriptional Signature and Enhances the Malignant Properties of Ewing's Sarcoma Cells In vitro
- (2010) D. N. T. Aryee et al. CANCER RESEARCH
- In vivo Dynamics and Distinct Functions of Hypoxia in Primary Tumor Growth and Organotropic Metastasis of Breast Cancer
- (2010) X. Lu et al. CANCER RESEARCH
- Aminoflavone, a Ligand of the Aryl Hydrocarbon Receptor, Inhibits HIF-1 Expression in an AhR-Independent Fashion
- (2010) E. Terzuoli et al. CANCER RESEARCH
- Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling
- (2010) S. Rey et al. CARDIOVASCULAR RESEARCH
- Hypoxia-activated prodrugs in cancer therapy: progress to the clinic
- (2010) William A Denny Future Oncology
- Phase II Study of Neoadjuvant Bevacizumab and Radiotherapy for Resectable Soft Tissue Sarcomas
- (2010) Sam S. Yoon et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Increased levels of hypoxia-inducible factor-1α are associated with Bcl-xL expression, tumor apoptosis, and clinical outcome in chondrosarcoma
- (2010) Changbao Chen et al. JOURNAL OF ORTHOPAEDIC RESEARCH
- Hypoxia-Inducible Factors and the Response to Hypoxic Stress
- (2010) Amar J. Majmundar et al. MOLECULAR CELL
- Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1α-induced metabolic reprograming
- (2010) F Zhao et al. ONCOGENE
- Hypoxia-Inducible Factor 1α Determines Gastric Cancer Chemosensitivity via Modulation of p53 and NF-κB
- (2010) Nadine Rohwer et al. PLoS One
- New Developments in Targeted Therapy for Soft Tissue Sarcoma
- (2010) Kristen N. Ganjoo Current Oncology Reports
- Novel Agents on the Horizon for Cancer Therapy
- (2009) W. W. Ma et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Hypoxia-Induced Lysyl Oxidase Is a Critical Mediator of Bone Marrow Cell Recruitment to Form the Premetastatic Niche
- (2009) Janine T. Erler et al. CANCER CELL
- Hypoxia-Regulated Delta-like 1 Homologue Enhances Cancer Cell Stemness and Tumorigenicity
- (2009) Y. Kim et al. CANCER RESEARCH
- A Three-Gene Signature for Outcome in Soft Tissue Sarcoma
- (2009) A.-C. Hoffmann et al. CLINICAL CANCER RESEARCH
- Emerging Roles of microRNAs in the Molecular Responses to Hypoxia
- (2009) Meredith Crosby et al. CURRENT PHARMACEUTICAL DESIGN
- HIF-1α is an unfavorable determinant of relapse in gastric cancer patients who underwent curative surgery followed by adjuvant 5-FU chemotherapy
- (2009) Jun Nakamura et al. INTERNATIONAL JOURNAL OF CANCER
- Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
- (2009) G L Semenza ONCOGENE
- Cross Species Genomic Analysis Identifies a Mouse Model as Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma
- (2009) Jeffrey K. Mito et al. PLoS One
- HIF2 inhibition promotes p53 pathway activity, tumor cell death, and radiation responses
- (2009) J. A. Bertout et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells
- (2009) K. Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis
- (2009) X. Xia et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Effects of lentivirus-mediated HIF-1α knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells
- (2008) J Hao et al. CANCER GENE THERAPY
- Phosphorylated ERα, HIF-1α, and MAPK Signaling As Predictors of Primary Endocrine Treatment Response and Resistance in Patients With Breast Cancer
- (2008) Daniele Generali et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Imaging of Hypoxia
- (2008) K. A. Krohn et al. JOURNAL OF NUCLEAR MEDICINE
- Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity
- (2008) R. Sullivan et al. MOLECULAR CANCER THERAPEUTICS
- A RNA antagonist of hypoxia-inducible factor-1 , EZN-2968, inhibits tumor cell growth
- (2008) L. M. Greenberger et al. MOLECULAR CANCER THERAPEUTICS
- Digoxin and other cardiac glycosides inhibit HIF-1 synthesis and block tumor growth
- (2008) H. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hypoxia Enhances Tumor Stemness by Increasing the Invasive and Tumorigenic Side Population Fraction
- (2008) Bikul Das et al. STEM CELLS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started